Global Gastrointestinal Stromal Tumors Market Research Report Information By Indication (Stomach, Small Intestine, Other Indication), Diagnosis (Endoscopic Ultrasound, Biopsy, Others), Treatment (Surgery, Targeted Therapy), and End-User– Global Forecast Till 2032

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Gastrointestinal Stromal Tumors Market, by Indication

6.1 Introduction

6.2 Stomach

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

6.3 Small intestine

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

6.4 Large intestine (colon)

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

6.5 Others

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

Chapter 7. Global Gastrointestinal Stromal Tumors Market, by Diagnosis

7.1 Introduction

7.2 Imaging Studies

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.3 Plain abdominal radiography

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.4 Barium and air (double-contrast) series

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.5 Return-flow enema

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.6 Computed tomography scans of the abdomen and pelvis

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.6 Magnetic resonance imaging

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.6 Endoscopy

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.6 Endoscopic ultrasonography

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.6 Others

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

Chapter 8. Global Gastrointestinal Stromal Tumors Market, by Treatment

8.1 Introduction

8.2 Surgery

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

8.3 Targeted therapy

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

8.3.1 Tyrosine kinase inhibitors (TKIs)

8.3.2 Imatinib

8.3.3 Sunitinib

8.3.4 Regorafenib

8.3.5 Others

8.4 Radiation therapy

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

8.5 Chemotherapy

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

8.6 Ablation

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

8.6.1 Radiofrequency ablation (RFA)

8.6.2 Ethanol (alcohol) ablation

8.6.3 Microwave thermotherapy

8.6.4 Cryosurgery (cryotherapy)

8.6.5 Others

8.7 Embolization

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

8.8 Others

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

Chapter 9. Global Gastrointestinal Stromal Tumors Market, by End-User

9.1 Introduction

9.2 Hospitals & clinics

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

9.3 Ambulatory surgical centers

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

9.4 Others

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

Chapter 10. Global Gastrointestinal Stromal Tumors Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K.

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 The Middle East

10.5.2 Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

Chapter 12. Company Profiles

12.1 Bayer AG

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 Novartis AG

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Immunicum AB

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 F. Hoffmann-La Roche Ltd.

12.4.1 Company Overview

12.4.2 Technology/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 AB SCIENCES

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Arog Pharmaceuticals, Inc.

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Boston Biomedical, Inc.

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financial Overview

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Sun Pharmaceutical Industries Limited

12.8.1 Overview

12.8.2 Product/ Technology Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Pfizer Inc.

12.9.1 Overview

12.9.2 Product Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 NATCO Pharma Limited

12.10.1 Overview

12.10.2 Product Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 Others

Chapter 17 Appendix

LIST OF TABLES

Table 1 Global Gastrointestinal Stromal Tumors Market Synopsis, 2023-2030

Table 2 Global Gastrointestinal Stromal Tumors Market Estimates and Forecast, 2023-2030, (USD Million)

Table 3 Global Gastrointestinal Stromal Tumors Market, by Region, 2023-2030, (USD Million)

Table 4 Global Gastrointestinal Stromal Tumors Market, by Indication, 2023-2030, (USD Million)

Table 5 Global Gastrointestinal Stromal Tumors Market, by Diagnosis, 2023-2030, (USD Million)

Table 6 Global Gastrointestinal Stromal Tumors Market, by Treatment, 2023-2030, (USD Million)

Table 7 Global Gastrointestinal Stromal Tumors Market, by End-User, 2023-2030, (USD Million)

Table 8 North America Global Gastrointestinal Stromal Tumors Market, by End-User, 2023-2030, (USD Million)

Table 9 North America Global Gastrointestinal Stromal Tumors Market, by Diagnosis, 2023-2030, (USD Million)

Table 10 North America Global Gastrointestinal Stromal Tumors Market, by Treatment, 2023-2030, (USD Million)

Table 11 North America Global Gastrointestinal Stromal Tumors Market, by End-User, 2023-2030, (USD Million)

Table 12 U.S. Gastrointestinal Stromal Tumors Market, by End-User, 2023-2030, (USD Million)

Table 13 U.S. Gastrointestinal Stromal Tumors Market, by Diagnosis, 2023-2030, (USD Million)

Table 14 U.S. Gastrointestinal Stromal Tumors Market, by Treatment, 2023-2030, (USD Million)

Table 15 U.S. Gastrointestinal Stromal Tumors Market, by End-User, 2023-2030, (USD Million)

Table 16 Canada Gastrointestinal Stromal Tumors Market, by End-User, 2023-2030, (USD Million)

Table 17 Canada Gastrointestinal Stromal Tumors Market, by Diagnosis, 2023-2030, (USD Million)

Table 18 Canada Gastrointestinal Stromal Tumors Market, by Treatment, 2023-2030, (USD Million)

Table 19 Canada Gastrointestinal Stromal Tumors Market, by End-User, 2023-2030, (USD Million)

Table 20 Canada Gastrointestinal Stromal Tumors Market, by End-User, 2023-2030, (USD Million)

Table 21 South America Gastrointestinal Stromal Tumors Market, by End-User, 2023-2030, (USD Million)

Table 22 South America Gastrointestinal Stromal Tumors Market, by Diagnosis, 2023-2030, (USD Million)

Table 23 South America Gastrointestinal Stromal Tumors Market, by Treatment, 2023-2030, (USD Million)

Table 24 South America Gastrointestinal Stromal Tumors Market, by End-User, 2023-2030, (USD Million)

Table 25 Europe Gastrointestinal Stromal Tumors Market, by Indication, 2023-2030, (USD Million)

Table 26 Europe Gastrointestinal Stromal Tumors Market, by Diagnosis, 2023-2030, (USD Million)

Table 27 Europe Gastrointestinal Stromal Tumors Market, by Treatment, 2023-2030, (USD Million)

Table 28 Europe Gastrointestinal Stromal Tumors Market, by End-User, 2023-2030, (USD Million)

Table 29 Western Europe Gastrointestinal Stromal Tumors Market, by End-User, 2023-2030, (USD Million)

Table 30 Western Europe Gastrointestinal Stromal Tumors Market, by Indication, 2023-2030, (USD Million)

Table 31 Western Europe Gastrointestinal Stromal Tumors Market, by Diagnosis, 2023-2030, (USD Million)

Table 32 Western Europe Gastrointestinal Stromal Tumors Market, by Treatment, 2023-2030, (USD Million)

Table 33 Western Europe Gastrointestinal Stromal Tumors Market, by End-User, 2023-2030, (USD Million)

Table 24 Eastern Europe Gastrointestinal Stromal Tumors Market, by Indication, 2023-2030, (USD Million)

Table 35 Eastern Europe Gastrointestinal Stromal Tumors Market, by Diagnosis, 2023-2030, (USD Million)

Table 36 Eastern Europe Gastrointestinal Stromal Tumors Market, by Treatment, 2023-2030, (USD Million)

Table 37 Eastern Europe Gastrointestinal Stromal Tumors Market, by End-User, 2023-2030, (USD Million)

Table 38 Asia Pacific Gastrointestinal Stromal Tumors Market, by Indication, 2023-2030, (USD Million)

Table 39 Asia Pacific Gastrointestinal Stromal Tumors Market, by Diagnosis, 2023-2030, (USD Million)

Table 40 Asia Pacific Gastrointestinal Stromal Tumors Market, by Treatment, 2023-2030, (USD Million)

Table 41 Asia Pacific Gastrointestinal Stromal Tumors Market, by End-User, 2023-2030, (USD Million)

Table 42 Middle East & Africa Gastrointestinal Stromal Tumors Market, by Indication, 2023-2030, (USD Million)

Table 43 Middle East & Africa Gastrointestinal Stromal Tumors Market, by Diagnosis, 2023-2030, (USD Million)

Table 44 Middle East & Africa Gastrointestinal Stromal Tumors Market, by Treatment 2023-2030, (USD Million)

Table 45 Middle East & Africa Gastrointestinal Stromal Tumors Market, by End-User 2023-2030, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Gastrointestinal Stromal Tumors Market

Figure 3 Segmentation Market Dynamics for Global Gastrointestinal Stromal Tumors Market

Figure 4 Global Gastrointestinal Stromal Tumors Market Share, by Indication 2023

Figure 5 Global Gastrointestinal Stromal Tumors Market Share, by Diagnosis 2023

Figure 6 Global Gastrointestinal Stromal Tumors Market Share, by Treatment 2023

Figure 7 Global Gastrointestinal Stromal Tumors Market Share, by End-User 2023

Figure 8 Global Gastrointestinal Stromal Tumors Market Share, by Region, 2023

Figure 9 North America Gastrointestinal Stromal Tumors Market Share, by Country, 2023

Figure 10 Europe Gastrointestinal Stromal Tumors Market Share, by Country, 2023

Figure 11 Asia Pacific Gastrointestinal Stromal Tumors Market Share, by Country, 2023

Figure 12 Middle East & Africa Gastrointestinal Stromal Tumors Market Share, by Country, 2023

Figure 13 Global Gastrointestinal Stromal Tumors Market: Company Share Analysis, 2023 (%)

Figure 14 Bayer AG: Key Financials

Figure 15 Bayer AG: Segmental Revenue

Figure 16 Bayer AG: Geographical Revenue

Figure 17 Novartis AG: Key Financials

Figure 18 Novartis AG: Segmental Revenue

Figure 19 Novartis AG: Geographical Revenue

Figure 20 Immunicum AB: Key Financials

Figure 21 Immunicum AB: Segmental Revenue

Figure 22 Immunicum AB: Geographical Revenue

Figure 23 F. Hoffmann-La Roche Ltd.: Key Financials

Figure 24 F. Hoffmann-La Roche Ltd.: Segmental Revenue

Figure 25 F. Hoffmann-La Roche Ltd.: Geographical Revenue

Figure 26 AB SCIENCES: Key Financials

Figure 27 AB SCIENCES: Segmental Revenue

Figure 28 AB SCIENCES. Geographical Revenue

Figure 29 Arog Pharmaceuticals, Inc.: Key Financials

Figure 30 Arog Pharmaceuticals, Inc.: Segmental Revenue

Figure 31 Arog Pharmaceuticals, Inc.: Geographical Revenue

Figure 32 F. Hoffman- La Roche: Key Financials

Figure 33 F. Hoffman- La Roche: Segmental Revenue

Figure 34 F. Hoffman- La Roche: Geographical Revenue

Figure 35 Cascade Healthcare Products, Inc: Key Financials

Figure 36 Cascade Healthcare Products, Inc: Segmental Revenue

Figure 37 Cascade Healthcare Products, Inc: Geographical Revenue

Figure 38 Pfizer Inc.: Key Financials

Figure 39 Pfizer Inc.: Segmental Revenue

Figure 40 Pfizer Inc.: Geographical Revenue

Figure 41 NATCO Pharma Limited: Key Financials

Figure 42 NATCO Pharma Limited: Segmental Revenue

Figure 43 NATCO Pharma Limited: Geographical Revenue

Figure 44 Flexicare Medical Limited: Key Financials

Figure 45 Flexicare Medical Limited Segmental Revenue

Figure 46 Flexicare Medical Limited: Geographical Revenue

Figure 47 Farla medical Ltd.: Key Financials

Figure 48 Farla medical Ltd.: Segmental Revenue

Figure 49 Farla medical Ltd.: Geographical Revenue

Figure 50 Jiangsu Delfu Co. Ltd: Key Financials

Figure 51 Jiangsu Delfu Co. Ltd: Segmental Revenue

Figure 52 Jiangsu Delfu Co. Ltd: Geographical Revenue

Figure 53 Biocon Ltd: Key Financials

Figure 54 Biocon Ltd: Segmental Revenue

Figure 55 Biocon Ltd: Geographical Revenue